TY - JOUR
T1 - Management of neurosarcoidosis
T2 - A clinical challenge
AU - Voortman, Mareye
AU - Drent, Marjolein
AU - Baughman, Robert P.
N1 - Funding Information:
The preparation of this review was supported by a research grant from the Netherlands Organization for Health Research and Development, ZonMw (project number 842002005) and the ild care foundation: www.ildcare.nl.
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Purpose of reviewSarcoidosis is a complex disease with many faces, and the clinical manifestation and course of neurosarcoidosis are particularly variable. Although neurosarcoidosis occurs in up to 10% of sarcoidosis patients, it can lead to significant morbidity and some mortality.Recent findingsThree criteria are usually required for a diagnosis of (neuro)sarcoidosis: clinical and radiologic manifestations, noncaseating granulomas, and no evidence of alternative disease. Recent guidelines have helped to clarify criteria for diagnosing neurosarcoidosis. No firm guidelines exist on whether, when, and how treatment should be started. Treatment depends on the presentation and distribution, extensiveness, and severity of neurosarcoidosis. As regards evidence-based treatment, only a few randomized controlled trials have been done. Hence, several aspects of (neuro)sarcoidosis management are not fully addressed by the current literature.SummarySignificant advances have been made in the potential and accuracy of diagnostics for neurosarcoidosis. Treatment should be approached within the context of the patient's anticipated clinical course, avoidance of adverse drug effects, and, if necessary, from the perspective of the comprehensive management of a chronic disease. A multidisciplinary approach to the management of sarcoidosis is strongly recommended.
AB - Purpose of reviewSarcoidosis is a complex disease with many faces, and the clinical manifestation and course of neurosarcoidosis are particularly variable. Although neurosarcoidosis occurs in up to 10% of sarcoidosis patients, it can lead to significant morbidity and some mortality.Recent findingsThree criteria are usually required for a diagnosis of (neuro)sarcoidosis: clinical and radiologic manifestations, noncaseating granulomas, and no evidence of alternative disease. Recent guidelines have helped to clarify criteria for diagnosing neurosarcoidosis. No firm guidelines exist on whether, when, and how treatment should be started. Treatment depends on the presentation and distribution, extensiveness, and severity of neurosarcoidosis. As regards evidence-based treatment, only a few randomized controlled trials have been done. Hence, several aspects of (neuro)sarcoidosis management are not fully addressed by the current literature.SummarySignificant advances have been made in the potential and accuracy of diagnostics for neurosarcoidosis. Treatment should be approached within the context of the patient's anticipated clinical course, avoidance of adverse drug effects, and, if necessary, from the perspective of the comprehensive management of a chronic disease. A multidisciplinary approach to the management of sarcoidosis is strongly recommended.
KW - diagnostic procedure
KW - infliximab
KW - multidisciplinary management
KW - neurosarcoidosis
KW - sarcoidosis
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85065400928&partnerID=8YFLogxK
U2 - 10.1097/WCO.0000000000000684
DO - 10.1097/WCO.0000000000000684
M3 - Review article
C2 - 30865007
AN - SCOPUS:85065400928
SN - 1350-7540
VL - 32
SP - 475
EP - 483
JO - Current Opinion in Neurology
JF - Current Opinion in Neurology
IS - 3
ER -